{
  "ticker": "AXE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973063",
  "id": "02973063",
  "pages": 5,
  "price_sensitive": false,
  "date": "20250728",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m62qcztql9rk.pdf",
  "summary": "### **Material Information Summary (ASX: AXE \u2013 28 July 2025)**  \n\n#### **Key Highlights:**  \n- **Biosensor Advancements:** Significant accuracy improvements in potassium-level detection in blood; new chip design and readout system near final form, with test results expected **October 2025**.  \n- **Platform Expansion:** Biosensor tech successfully demonstrated detection of **lithium ions**, opening opportunities in healthcare, environmental, and industrial applications.  \n- **Regulatory Progress:** Engaging medical experts for **clinical trials**, targeting approvals in **Australia (TGA)** and **US (FDA)**.  \n- **Market Potential:** Targeting **US$3B+ kidney disease market**; potential cost savings for Medicare via at-home potassium monitoring.  \n- **Partnership/Collaboration:** Progress with **Hylid** on sensor-compatible cartridges; prototype components expected by **end of 2025**.  \n\n*No capital raising, financials, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 2160,
    "completion_tokens": 206,
    "total_tokens": 2366,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:00:09.136296"
}